Skip to content

A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524168-39-00
Enrollment
23
Registered
2026-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

​​Platinum-Resistant ovarian cancer​

Interventions

None listed

Sponsors

Stemline Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 24, 2026